atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference | Psychedelic Invest

NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai’s supervisory board (“Board”) subject to applicable legal requirements. Scott…

Regulating artificial intelligence doesn’t have to be complicated, some experts say

Artificial intelligence has the potential to revolutionize how drugs are discovered and change how hospitals deliver care to patients. But AI also comes with the

July 3, 2024

Gene therapy shows promise for arrhythmogenic cardiomyopathy

Researchers evaluated the effectiveness of adeno-associated virus (AAV)-mediated Plakophilin 2 (PKP2) delivery in treating arrhythmogenic cardiomyopathy (ACM).

December 12, 2023

Deep brain stimulation shows promise for post-stroke rehabilitation

A first-in-human trial of deep brain stimulation (DBS) for post-stroke rehabilitation patients by Cleveland Clinic researchers has shown that using DBS to target the dentate

August 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.